KHTR.F Stock Overview
Operates as a specialty pharmaceutical company that focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceutical products in Canada and Latin America. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for KHTR.F from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Knight Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$4.32 |
| 52 Week High | CA$4.55 |
| 52 Week Low | CA$3.48 |
| Beta | 0.42 |
| 1 Month Change | 8.62% |
| 3 Month Change | 15.82% |
| 1 Year Change | 8.27% |
| 3 Year Change | -2.92% |
| 5 Year Change | 25.58% |
| Change since IPO | -21.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| KHTR.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 14.0% | -2.5% | 0.3% |
| 1Y | 8.3% | -0.1% | 9.0% |
Return vs Industry: KHTR.F exceeded the US Pharmaceuticals industry which returned -0.1% over the past year.
Return vs Market: KHTR.F matched the US Market which returned 9% over the past year.
Price Volatility
| KHTR.F volatility | |
|---|---|
| KHTR.F Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.4% |
Stable Share Price: KHTR.F has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KHTR.F's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 725 | Samira Sakhia | www.knighttx.com |
Knight Therapeutics Inc. operates as a specialty pharmaceutical company that focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceutical products in Canada and Latin America. The company was founded in 2014 and is based in Montreal, Canada. It operates in additional locations in Latin America, such as Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Mexico, Paraguay, Peru, and Uruguay.
Knight Therapeutics Inc. Fundamentals Summary
| KHTR.F fundamental statistics | |
|---|---|
| Market cap | US$418.18m |
| Earnings (TTM) | -US$21.51m |
| Revenue (TTM) | US$244.09m |
1.8x
P/S Ratio-20.0x
P/E RatioIs KHTR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KHTR.F income statement (TTM) | |
|---|---|
| Revenue | CA$348.64m |
| Cost of Revenue | CA$180.37m |
| Gross Profit | CA$168.27m |
| Other Expenses | CA$199.00m |
| Earnings | -CA$30.73m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 20, 2025
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 48.26% |
| Net Profit Margin | -8.81% |
| Debt/Equity Ratio | 6.7% |
How did KHTR.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/17 02:05 |
| End of Day Share Price | 2025/03/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Knight Therapeutics Inc. is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Kideckel | Beacon Securities Limited |
| David Martin | Bloom Burton & Co. |
| Tania Armstrong-Whitworth | Canaccord Genuity |